Application of Bioinformatics in Cancers

Edited by
November 2019
418 pages
  • ISBN978-3-03921-788-5 (Paperback)
  • ISBN978-3-03921-789-2 (PDF)

This book is a reprint of the Special Issue Application of Bioinformatics in Cancers that was published in

Biology & Life Sciences
Medicine & Pharmacology
This collection of 25 research papers comprised of 22 original articles and 3 reviews is brought together from international leaders in bioinformatics and biostatistics. The collection highlights recent computational advances that improve the ability to analyze highly complex data sets to identify factors critical to cancer biology. Novel deep learning algorithms represent an emerging and highly valuable approach for collecting, characterizing and predicting clinical outcomes data. The collection highlights several of these approaches that are likely to become the foundation of research and clinical practice in the future. In fact, many of these technologies reveal new insights about basic cancer mechanisms by integrating data sets and structures that were previously immiscible. Accordingly, the series presented here bring forward a wide range of artificial intelligence approaches and statistical methods that can be applied to imaging and genomics data sets to identify previously unrecognized features that are critical for cancer. Our hope is that these articles will serve as a foundation for future research as the field of cancer biology transitions to integrating electronic health record, imaging, genomics and other complex datasets in order to develop new strategies that improve the overall health of individual patients.
  • Paperback
License and Copyright
© 2020 by the authors; CC BY license
comorbidity score; mortality; locoregionally advanced; HNSCC; curative surgery; traditional Chinese medicine; health strengthening herb; cancer treatment; network pharmacology; network target; high-throughput analysis; brain metastases; colorectal cancer; KRAS mutation; PD-L1; tumor infiltrating lymphocytes; drug resistance; gefitinib; erlotinib; biostatistics; bioinformatics; Bufadienolide-like chemicals; molecular mechanism; anti-cancer; bioinformatics; cancer; brain; pathophysiology; imaging; machine learning; extreme learning; deep learning; neurological disorders; pancreatic cancer; TCGA; curation; DNA; RNA; protein; single-biomarkers; multiple-biomarkers; cancer-related pathways; colorectal cancer; DNA sequence profile; Monte Carlo; mixture of normal distributions; somatic mutation; tumor; mutable motif; activation induced deaminase; AID/APOBEC; transcriptional signatures; copy number variation; copy number aberration; TCGA mining; cancer CRISPR; firehose; gene signature extraction; gene loss biomarkers; gene inactivation biomarkers; biomarker discovery; chemotherapy; microarray; ovarian cancer; predictive model; machine learning; overall survival; observed survival interval; skin cutaneous melanoma; The Cancer Genome Atlas; omics; breast cancer prognosis; artificial intelligence; machine learning; decision support systems; cancer prognosis; independent prognostic power; omics profiles; histopathological imaging features; cancer; intratumor heterogeneity; genomic instability; epigenetics; mitochondrial metabolism; miRNAs; cancer biomarkers; breast cancer detection; machine learning; feature selection; classification; denoising autoencoders; breast cancer; feature extraction and interpretation; concatenated deep feature; cancer modeling; interaction; histopathological imaging; clinical/environmental factors; oral cancer; miRNA; bioinformatics; datasets; biomarkers; TCGA; GEO DataSets; hormone sensitive cancers; breast cancer; StAR; estrogen; steroidogenic enzymes; hTERT; telomerase; telomeres; alternative splicing; network analysis; hierarchical clustering analysis; differential gene expression analysis; cancer biomarker; diseases genes; variable selection; false discovery rate; knockoffs; bioinformatics; copy number variation; cell-free DNA; methylation; mutation; next generation sequencing; self-organizing map; head and neck cancer; treatment de-escalation; HP; molecular subtypes; tumor microenvironment; Bioinformatics tool; R package; machine learning; meta-analysis; biomarker signature; gene expression analysis; survival analysis; functional analysis; bioinformatics; machine learning; artificial intelligence; Network Analysis; single-cell sequencing; circulating tumor DNA (ctDNA); Neoantigen Prediction; precision medicine; Computational Immunology